Agkisacucetin protein, Agkistrodon acutus clinical trials
Also written Anfibatide.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses agkisacucetin protein, Agkistrodon acutus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- Anfibatide
- 4
Studies by the year they started
5 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses agkisacucetin protein, Agkistrodon acutus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Anfibatide Phase Ib-IIa Clinical TrialCompletedPhase 1/2Lee's Pharmaceutical LimitedNCT01585259Written as AnfibatideHow we know
- Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy VolunteersSuspendedPhase 1Lee's Pharmaceutical LimitedNCT04404790Written as Anfibatide 5 IU/60kgHow we know
- A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)Status unknownPhase 2Lee's Pharmaceutical LimitedNCT04021173Written as AnfibatideHow we know
- Anfibatide Treatment in STEMI PatientsStatus unknownPhase 2Lee's Pharmaceutical LimitedNCT02495012Written as AnfibatideHow we know
- Anfibatide Phase 1 Clinical Trial in Healthy VolunteersCompletedPhase 1Lee's Pharmaceutical LimitedNCT01588132Written as AnfibatideHow we know
Codes
What other systems call agkisacucetin protein, Agkistrodon acutus · ClinicalTrials.gg INT000087
- MeSH (NLM) C000592236agkisacucetin protein, Agkistrodon acutusOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592236 | agkisacucetin protein, Agkistrodon acutus | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.